This research is Trending!
September 17, 2026European Heart Journal
Meta-analyses limitations and the compelling case for a contemporary, pragmatic trial of clopidogrel vs aspirin for secondary prevention of coronary heart disease: clopidogrel is not superior to aspirin in non-East Asian patients
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceKey expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“In summary, no randomized controlled trial (RCT) has demonstrated the superiority of clopidogrel over aspirin in non-East Asian patients with coronary artery disease (CAD).”
MVMarco ValgimigliCardiologist, Cardiocentro Ticino Institute and University of Bern
“This interpretation is not supported by the data because we had already shown that the HR for clopidogrel vs aspirin for major adverse cardiovascular events (MACE) was.82 (95% CI.70–.95) in Asian trials and.93 (95% CI.82–1.05) in non-Asian trials, without significant interaction (P interaction =.20).”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Galli et al. (2026) studied this question.